MYASTHENIA GRAVIS, GENERALIZED
Clinical trials for MYASTHENIA GRAVIS, GENERALIZED explained in plain language.
Never miss a new study
Get alerted when new MYASTHENIA GRAVIS, GENERALIZED trials appear
Sign up with your email to follow new studies for MYASTHENIA GRAVIS, GENERALIZED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug offers hope to free elderly patients from steroid side effects
Disease control Recruiting nowThis study is testing whether a newer drug called efgartigimod can help elderly patients with generalized myasthenia gravis reduce their steroid doses. Myasthenia gravis causes muscle weakness, and steroids are commonly used but cause serious side effects like diabetes and high b…
Matched conditions: MYASTHENIA GRAVIS, GENERALIZED
Phase: PHASE4 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New drug study aims to help people with debilitating muscle disease regain daily function
Disease control Recruiting nowThis study is observing how well the drug ravulizumab helps adults in Poland with generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness. Researchers will follow 50 patients for about 3 years to see if the treatment improves their ability to perform dai…
Matched conditions: MYASTHENIA GRAVIS, GENERALIZED
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Massive 10-Year health data hunt launched for brain inflammation mysteries
Knowledge-focused Recruiting nowThis is a long-term research project gathering health information from 10,000 people in the U.S. to build a detailed picture of brain inflammation and related conditions like Long COVID, ME/CFS, and autoimmune diseases. Participants, including both affected and healthy individual…
Matched conditions: MYASTHENIA GRAVIS, GENERALIZED
Sponsor: Brain Inflammation Collaborative • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:19 UTC